Insulin glulisine
From Wikipedia, the free encyclopedia
(Redirected from Apidra)
 |
This article needs attention from an expert on the subject. See the talk page for details. WikiProject Pharmacology or the Pharmacology Portal may be able to help recruit an expert. (March 2010) |
| Clinical data | |
|---|---|
| Trade names | Apidra |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607033 |
| Pregnancy cat. | C (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Subcutaneous |
| Identifiers | |
| CAS number | 207748-29-6  |
| ATC code | A10AB06 |
| DrugBank | DB01309 |
| UNII | 7XIY785AZD |
| KEGG | D04540  |
| Chemical data | |
| Formula | C258H384N64O78S6 |
| Mol. mass | 5823 g/mol |
 (what is this?) (verify) |
|
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.[4]
[edit] References
- ^ DailyMed: apidra (insulin glulisine) injection, solution
- ^ Jasek, W, ed. (2007) (in German). Austria-Codex (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-181-4.
- ^ Garnock-Jones, K. P.; Plosker, G. L. (2009). "Insulin Glulisine". Drugs 69 (8): 1035–1057. doi:10.2165/00003495-200969080-00006. PMID 19496630.
- ^ Drugs.com: Insulin Glulisine
[edit] External links
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
